Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway

Interstitial lung disease (ILD) is a serious side-effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment. Therefore, it is necessary to study underlying mechanisms for the development of pulmonary fibrosis induced by EGFR-TKI and potential approaches to attenuate...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Huang, Wenting, Li, Kunlin, Zhang, Kejun, Lin, Caiyu, Han, Rui, Lu, Conghua, Wang, Yubo, Chen, Hengyi, Sun, Fenfen, He, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791254/
https://www.ncbi.nlm.nih.gov/pubmed/26497205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791254/
https://www.ncbi.nlm.nih.gov/pubmed/26497205

Ejemplares similares